期刊
INTERNATIONAL JOURNAL OF UROLOGY
卷 25, 期 3, 页码 220-231出版社
WILEY
DOI: 10.1111/iju.13512
关键词
castration-resistant prostate cancer; precision medicine; prostate cancer; sequential therapy
资金
- Astellas
- Bayer
- Genetech
- Janssen
- Pfizer
- Sanofi
- Sotio
During the past decade, treatment strategies for patients with advanced prostate cancer involving stageIV (T4N0M0, N1M0 or M1) hormone-sensitive prostate cancer and recurrent prostate cancer after treatment with curative intent, as well as castration-resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel-T, radium-223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall survival. The appropriate use of these agents and the proper sequencing of these agents are still not optimized. The results of several recently reported randomized controlled trials and retrospective studies could assist in developing a treatment strategy for advanced prostate cancer. In addition, prospective studies and molecular characterization of tumors to address these issues are ongoing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据